Replicel Life Sciences Stock Net Income

REPCF Stock  USD 0  0  950.00%   
RepliCel Life Sciences fundamentals help investors to digest information that contributes to RepliCel Life's financial success or failures. It also enables traders to predict the movement of RepliCel Pink Sheet. The fundamental analysis module provides a way to measure RepliCel Life's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to RepliCel Life pink sheet.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

RepliCel Life Sciences Company Net Income Analysis

RepliCel Life's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

More About Net Income | All Equity Analysis

Current RepliCel Life Net Income

    
  (4.07 M)  
Most of RepliCel Life's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, RepliCel Life Sciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Competition

Based on the recorded statements, RepliCel Life Sciences reported net income of (4.07 Million). This is 101.19% lower than that of the Life Sciences Tools & Services sector and 105.82% lower than that of the Health Care industry. The net income for all United States stocks is 100.71% higher than that of the company.

RepliCel Net Income Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses RepliCel Life's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of RepliCel Life could also be used in its relative valuation, which is a method of valuing RepliCel Life by comparing valuation metrics of similar companies.
RepliCel Life is currently under evaluation in net income category among its peers.

RepliCel Fundamentals

About RepliCel Life Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze RepliCel Life Sciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of RepliCel Life using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of RepliCel Life Sciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in RepliCel Pink Sheet

RepliCel Life financial ratios help investors to determine whether RepliCel Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in RepliCel with respect to the benefits of owning RepliCel Life security.